Cupertino, California — Apple today announced it is awarding $10 million from its Advanced Manufacturing Fund to COPAN Diagnostics, a market leader in sample collection kits that play a critical role in COVID-19 testing. This funding will allow COPAN Diagnostics to rapidly accelerate their supply of sample collection kits for hospitals across the United States, expanding production from several thousand today to more than one million kits per week by early July. As part of this effort, Apple will support COPAN Diagnostics’ expansion to a new, larger facility in Southern California, with advanced equipment that Apple is helping design. This expansion is expected to create more than 50 new jobs.
“We feel a deep sense of responsibility to do everything we can to help medical workers, patients, and communities support the global response to COVID-19,” said Jeff Williams, Apple’s chief operating officer. “COPAN is one of the world’s most innovative manufacturers of sample collection kits for COVID-19 testing, and we’re thrilled to partner with them so they can expand as we work to address this critical issue for our nation. I couldn’t be prouder of our teams for bringing all of their energy, passion, and innovative spirit to supporting the country’s COVID-19 response.”
“We’re excited to forge this new relationship with Apple, whose teams are already making a huge difference with our efforts to scale up the production of our sample collection and transport kits,” said Norman Sharples, CEO of COPAN Diagnostics. “Collection and transport kits are a critical component in the fight against COVID-19. At COPAN, we’re excited and grateful for this partnership with Apple as our strong beliefs of innovation, quality, and excellence in manufacturing and design are perfectly aligned. Apple’s operational expertise will help us increase delivery of important pre-analytical tools for medical professionals across the country at this critical time.”